Figure 1.
Helicobacter hepaticus persistently colonises the lower bowel without inducing clinical enteric disease. (a) Aflatoxin study design. (b) Helicobacter hepaticus fluoresence in situ hybridisation. (c) Serum concentration of lipopolysaccharide (LPS) and high mobility group box-1 (HMGB1) in control (Ctrl), AFB1-, H hepaticus (Hh)- and AFB1 + Hh-treated groups.